Sherbrooke, Canada
TATUM bioscience, founded in 2019 in Canada, is pioneering advancements in the field of immunotherapy with its strikingly innovative slogan: "Multimodal nanofilament immunotherapy". This biotechnology startup is revolutionizing the therapeutic landscape by harnessing a groundbreaking modular synthetic biology platform aimed at developing multimodal nanofilaments. These nanofilaments are engineered to ignite comprehensive antitumor immune responses, achieving an unparalleled efficacy in tumor clearance.
The company operates at the intersection of multiple high-impact sectors, including Biopharma, Biotechnology, Health Care, Health and Wellness, and Life Sciences. TATUM bioscience garnered significant attention during its Pre Seed Round on April 1, 2020, securing investments from notable investors like BoxOne Ventures, Sherbrooke Innopole, and ACET Capital, underscoring the market’s confidence in its innovative approach and potential for transformative impact in oncology therapies.
